- Inositol supplementation offers no detectable reduction for preterm infant risk for most retinopathy of prematurity (ROP), intraventricular hemorrhage (IVH) grade 3/4, sepsis, or necrotizing enterocolitis.
- This Cochrane review relies largely on 2 recent randomized controlled trials.
Why this matters
- The authors say that inositol supplementation does not have sufficient support for routine nutritional management in these infants, regardless of their respiratory distress syndrome status.
- This review updates a 2015 analysis , which at the time viewed the evidence as “promising”; the authors say their current results argue against inositol supplementation and that infants in these studies need long-term follow-up.
- Although neonatal mortality reduction was associated with inositol supplementation (typical risk ratio [RR], 0.53; 95% CI, 0.31-0.91; 11 needed to benefit), infant deaths were not (typical RR, 0.89; 95% CI, 0.71-1.13), with low-quality evidence.
- No significant reductions for any ROP, necrotizing enterocolitis, sepsis, IVH grade 2+, bronchopulmonary dysplasia.
- 1 included study was terminated because of higher mortality rates in the inositol group.
- Analysis of 6 randomized controlled trials with 1177 infants.
- Funding: Izaak Walton Killam Health Center, Nova Scotia, Canada; Mount Sinai Hospital, Toronto; Vermont Oxford Network, USA.
- The included studies had serious or very serious limitations, the authors say.